Abstract
Tuberculosis (TB) is of increasing concern due to the recent emergence and spread of MDR-TB, XDR-TB, TDR-TB and HIV/AIDS pandemic. There is urgent need for novel antitubercular agents which can shorten the treatment duration. Based on isosteric replacement and 3D structural similarity between Linezolid, an oxazolidine antimycobacterial agent, we have designed novel 4-amino-3,5-di(substituted)thiazolin-2(3H)thione/ones, synthesized and evaluated for their antimycobacterial activity on Mycobacterium tuberculosis H37Rv strain. Some of the compounds exhibited potent antimycobacterial activity with MIC values in the range of 1-2 µg/mL. Active compounds were further screened against MDR-TB and XDR-TB strain and found to exhibit promising in vitro activity. Keywords: Antimycobacterial activity, MDR-TB, thiazolin-thione/ones, XDR-TB.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Anti-Infective Agents
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
